US equities
|
MU
$973.61
▲+4.83%
META
$612.72
▼-1.21%
TSLA
$401.31
▼-1.51%
SPCX
$144.31
▼-2.87%
SNDK
$1,377.84
▲+5.59%
NVDA
$217.95
▲+0.00%
SKHY
$163.14
▲+12.23%
STX
$674.93
▲+1.06%
MU
$973.61
▲+4.83%
META
$612.72
▼-1.21%
TSLA
$401.31
▼-1.51%
SPCX
$144.31
▼-2.87%
SNDK
$1,377.84
▲+5.59%
NVDA
$217.95
▲+0.00%
SKHY
$163.14
▲+12.23%
STX
$674.93
▲+1.06%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Corcept Therapeutics Incorporated - Common Stock
(NQ:
CORT
)
88.25
+0.66 (+0.75%)
Delayed Quote
Updated: 11:21 AM EDT, Oct 28, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Corcept Therapeutics Incorporated - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
22
23
Next >
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
October 27, 2026
From
Corcept Therapeutics Incorporated
Via
Business Wire
Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer
October 26, 2026
From
Corcept Therapeutics Incorporated
Via
Business Wire
Q2 earnings highs and lows: Collegium Pharmaceutical (NASDAQ:COLL) vs the rest of the branded pharmaceuticals stocks
October 25, 2026
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Collegium Pharmaceutical (NAS...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Q2 earnings highs and lows: Eli Lilly (NYSE:LLY) vs the rest of the branded pharmaceuticals stocks
October 22, 2026
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Corcept Therapeutics (NASDAQ:CORT) Combines Strong Growth With a Constructive Technical Setup
↗
September 17, 2026
Via
Chartmill
Corcept Therapeutics (NASDAQ:CORT) Surges 21% After Q2 Earnings Beat and Raised Guidance
↗
July 29, 2026
Via
Chartmill
Topics
Earnings
2 cash-producing stocks to research further and 1 we find risky
October 22, 2026
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
Via
StockStory
Topics
Energy
2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes
October 20, 2026
From
Corcept Therapeutics Incorporated
Via
Business Wire
1 Cash-Heavy Stock to Keep an Eye On and 2 We Question
October 15, 2026
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg...
Via
StockStory
Branded Pharmaceuticals Stocks Q2 In Review: Zoetis (NYSE:ZTS) Vs Peers
October 12, 2026
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking a...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
3 Reasons to Sell CORT and 1 Stock to Buy Instead
October 06, 2026
The past six months have been a windfall for Corcept’s shareholders. The company’s stock price has jumped 201%, hitting $122.93 per share. This was partly du...
Via
StockStory
Unpacking Q2 Earnings: Merck (NYSE:MRK) In The Context Of Other Branded Pharmaceuticals Stocks
September 28, 2026
Looking back on branded pharmaceuticals stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Merck (NYSE:MRK) and its peers. L...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Corcept Announces Planned Leadership Transition
September 23, 2026
From
Corcept Therapeutics Incorporated
Via
Business Wire
Branded Pharmaceuticals Stocks Q2 In Review: Phibro Animal Health (NASDAQ:PAHC) Vs Peers
September 22, 2026
Let’s dig into the relative performance of Phibro Animal Health (NASDAQ:PAHC) and its peers as we unravel the now-completed Q2 branded pharmaceuticals earnin...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
3 of Wall Street’s Favorite Stocks We Keep Off Our Radar
September 22, 2026
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
Via
StockStory
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)
September 18, 2026
From
Corcept Therapeutics Incorporated
Via
Business Wire
2 Healthcare Stocks to Research Further and 1 We Find Risky
September 16, 2026
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have be...
Via
StockStory
1 Growth Stock Set to Flourishand 2 We Brush Off
September 01, 2026
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil...
Via
StockStory
Topics
Supply Chain
Branded Pharmaceuticals Stocks Q2 Teardown: Bristol-Myers Squibb (NYSE:BMY) Vs The Rest
August 31, 2026
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceutical...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Q2 Rundown: Pfizer (NYSE:PFE) Vs Other Branded Pharmaceuticals Stocks
August 24, 2026
Let’s dig into the relative performance of Pfizer (NYSE:PFE) and its peers as we unravel the now-completed Q2 branded pharmaceuticals earnings season. Lookin...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
1 Mid-Cap Stock for Long-Term Investors and 2 That Underwhelm
August 21, 2026
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...
Via
StockStory
Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Corcept (NASDAQ:CORT)
August 19, 2026
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Corcept (NASDAQ:CORT) and its...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
1 Surging Stock to Own for Decades and 2 We Brush Off
August 13, 2026
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a ne...
Via
StockStory
3 Cash-Producing Stocks We Steer Clear Of
August 04, 2026
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
Via
StockStory
Corcept Therapeutics Q2 Earnings Call Highlights
↗
July 29, 2026
Corcept Therapeutics (NASDAQ:CORT) reported second-quarter 2026 revenue of $256.1 million, up 32% from the prior-year period, as sales from its Cushing’s syndrome franchise increased and its newly...
Via
MarketBeat
Topics
Earnings
Curious about the stocks that are showing activity after the closing bell on Wednesday?
↗
July 29, 2026
Via
Chartmill
Corcept (NASDAQ:CORT) Reports Bullish Q2 CY2026, Stock Jumps 17.4%
July 29, 2026
Biopharma company Corcept Therapeutics (NASDAQ:CORT) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 31.7% year on year t...
Via
StockStory
Topics
Artificial Intelligence
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
July 29, 2026
From
Corcept Therapeutics Incorporated
Via
Business Wire
Corcept (CORT) Q2 Earnings: What To Expect
July 27, 2026
Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results this Wednesday after market hours. Here’s what to expect. Corcept mi...
Via
StockStory
Topics
Artificial Intelligence
Why Corcept (CORT) Stock Is Down Today
July 27, 2026
What Happened? Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 2.9% in the morning session after Wolfe Research downgraded the stock to '...
Via
StockStory
< Previous
1
2
3
4
5
6
7
8
9
...
22
23
Next >
